Group 1 - The core point of the article is that Eton Pharma (06998) experienced a nearly 9% increase in stock price, currently trading at 2.95 HKD, with a trading volume of 3.5091 million HKD following the announcement of the completion of the first dosing in a Phase II clinical trial for the new drug EDP167 [1] - EDP167 is being tested in a multicenter, dose-exploration, open-label trial targeting adult patients with homozygous familial hypercholesterolemia (HoFH), with the primary endpoint being the change in LDL-C levels from baseline after 24 weeks of treatment, expected to complete the primary endpoint assessment by Q4 2026 [1] - On December 30, Eton Pharma completed a reverse acquisition with Jiahe Biotech, marking the official establishment of Eton Pharma and entering a new phase in strategic integration and development, with the Chinese stock name changing from "Jiahe Biotech" to "Eton Pharma" effective February 6, 2026 [1]
港股异动 | 亿腾嘉和(06998)尾盘涨近9% 旗下EDP167临床II期研究成功完成首例受试者给药